Can you explain to us, poof, how RNAi might compete with the transport of existing therapies like Herceptin (xB3-001), IL-1Ra (xB3-004), and other biologics across the BBB?
You have an irresponsible habit of posting with no analysis or context. For years it's been left to me and others to clean up the messes you've created.
Tell us the scope of possibilities with RNAi, how it might medically compete with RMT (xB3 and Denali's TV), what the manufacturing scenarios look like compared to RMT fusion proteins, etc, etc.
Time to belly up to the bar, poof. I suggest that you can't do it unless somebody else gives you the answers.
Note: The performance of biotech indexes and related share prices are irrelevant to these questions.
jd